Genetic Testing for All Women? Not a Solution to the Breast Cancer Epidemic
By Karuna Jaggar,
Huffington Post
| 09. 24. 2014
The perseverance and scientific innovation of Dr. Mary Claire King, the geneticist whose efforts to identify the BRCA genes were initially scoffed at by her peers, cannot be underestimated or underappreciated. Her drive and desire to find better tools to address the breast cancer epidemic are shared by activists, researchers, geneticist, and patients alike. But her new recommendation, published in the Journal of the American Medical Association -- that all women in the United States over age 30 be screened for BRCA mutations linked to breast and ovarian cancer -- fails as a matter of public health to recognize the significant limitations, and harms, of mass genetic testing in the current health care environment.
In proposing that genetic testing for the BRCA1 and BRCA2 genes become routine for all women over age 30, Dr. King focuses only on what she sees as the potential benefit, of identifying women with genetic mutations that increase their risk of cancer, and minimizes the harms that result from exposing all 105,000,000 women age 30 and over in the U.S. to genetic testing without access...
Related Articles
By Katie Palmer and Usha Lee McFarling, Stat | 09.03.2024
Photo by Hush Naidoo Jade Photography on Unsplash
Pediatrician Alexandra Epee-Bounya had had enough. In her 20 years caring for children in Boston, she had seen hundreds of kids with suspected urinary tract infections. Each time, she’d turn to a...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...
By Antonio Regalado, MIT Technology Review | 08.22.2024
In 2016, I attended a large meeting of journalists in Washington, DC. The keynote speaker was Jennifer Doudna, who just a few years before had co-invented CRISPR, a revolutionary method of changing genes that was sweeping across biology labs because...